Impel Pharmaceuticals Inc. (IMPL) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Impel Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update
August 15, 2022 8:05 AM EDTTrudhesa® TRxs Grew 48% in Q2 2022 to Over 13K: Net Product Revenue Increased 59% Over Q1 2022 to $2.8 Million
Sales Force Expanded by 50% to Capitalize on Prescription Momentum and Market Opportunity
Company Reiterated Prescription Guidance Range of 70-85K TRxs for 2022
Initiated Proof-of-Concept Study for INP105 in Autism Spectrum Disorder
Impel to Host Investor Conference Call Today at 8:30 A.M. ET
SEATTLE, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:... More
